Renalytix PLC (ADR) - SIC # 7372 - PREPACKAGED SOFTWARE

Ticker Exchange SIC # Website Latest Ticker
RNLX Nasdaq 7372 https://renalytix.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Renalytix PLC (ADR)

Renalytix Announces Financing with Expected Size of up to $4 Million - Apr 8th, 2024 11:00 am
3 Ridiculously Enticing Stocks to Buy for Under a Buck - Mar 25th, 2024 7:58 pm
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD) - Mar 14th, 2024 11:00 am
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024 - Feb 15th, 2024 12:00 pm
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Feb 9th, 2024 2:00 pm
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease - Jan 10th, 2024 12:00 pm
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 - Nov 14th, 2023 12:00 pm
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14 - Nov 7th, 2023 12:00 pm
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock - Oct 16th, 2023 4:00 pm
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix - Oct 6th, 2023 11:00 am
Renalytix AI PLC Sponsored ADR (RNLX) Loses -44.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Oct 5th, 2023 1:35 pm
Renalytix Plc (NASDAQ:RNLX) Q4 2023 Earnings Call Transcript - Oct 3rd, 2023 12:45 pm
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28 - Sep 25th, 2023 11:00 am
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer - Sep 7th, 2023 11:00 am
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd - Aug 3rd, 2023 11:00 am
Renalytix Announces Middle East Distribution Agreement with Vector Pharma - Jul 21st, 2023 11:00 am
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions - Jul 7th, 2023 11:00 am
Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors - Jul 3rd, 2023 11:00 am
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease - Jun 29th, 2023 10:01 pm
KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences - Jun 15th, 2023 11:00 am